Reconsidering Interferon-Gamma in Adult Chronic Granulomatous Disease
Six infection-free years into adulthood, a patient with X-linked chronic granulomatous disease asks whether the interferon-gamma injections that shaped his childhood are still doing the work he's always assumed they were.
Owen K., 26, just finished a graduate accounting program and starts his first real job next month, a milestone that feels almost unremarkable to people who didn't spend their childhood in and out of the hospital for staph abscesses and fungal pneumonia the way he did. X-linked chronic granulomatous disease was diagnosed when he was eleven months old, and he has been on the same three-drug prophylaxis regimen — trimethoprim-sulfamethoxazole, itraconazole, and interferon-gamma injections three times weekly — since early childhood. He gave himself his first injection at fourteen and has kept doing it ever since, describing the fevers and body aches that follow most doses as, in his words, 'the tax I've paid for staying out of the hospital.' He has not had a serious infection requiring hospitalization in six years, the longest stretch of his life.
The evidence behind that regimen is real but old, and was never built specifically around adults. The trial that established interferon-gamma's role — the International Chronic Granulomatous Disease Cooperative Study Group's placebo-controlled study, published in 1991 — randomized 128 patients and found a 67 percent reduction in the relative risk of serious infection, a result robust enough that it changed practice worldwide and has never been directly repeated since; nobody re-runs a placebo trial once a treatment effect that large is established.
What that trial couldn't answer, because it wasn't designed to, is whether the same benefit still holds decades into an individual patient's life. It ran for twelve months in a cohort whose median age was 15; Owen has now been on the drug for roughly twenty-two years, more than twenty of them beyond anything the trial observed. Its infection rates were disputed almost immediately — Mouy and colleagues, writing to the same journal from Paris and Zurich later that year, reported that their own antibiotic-prophylaxis cohorts never approached the infection rate the trial's placebo arm recorded, which if correct would inflate the apparent benefit. And the genotype cuts against him rather than for him: X-linked, gp91phox-deficient disease like his carries the more severe phenotype and the worse survival of the two inheritance patterns, and the 1991 trial found interferon-gamma beneficial regardless of which one a patient had. So the case for reconsidering is not that the drug works less well in him. It is that his own six infection-free adult years sit entirely outside the window anyone has ever measured.
Deciding whether six good years are the drug's doing or his own luck
I'd keep all three agents unchanged. The International CGD Cooperative Study Group's 1991 trial showed a 67 percent reduction in the relative risk of serious infection — and it found that benefit regardless of inheritance pattern, which matters here, because his is the X-linked form that carries the more severe phenotype and the worse survival. It has never been superseded by a trial showing it is safe to stop in adulthood. Six good years is genuinely reassuring, but CGD's serious infections are exactly the kind of low-frequency, high-severity events where the absence of a bad outcome over a defined window doesn't reliably tell you the underlying risk has actually changed.
I want to be careful not to argue with the trial, because it is a good trial and it has never been formally superseded. I'm not disputing a single one of its numbers.
But look at what it actually was. Twelve months of follow-up, median age 15, and an effect size Mouy and colleagues in Paris and Zurich questioned in print within the year, on the grounds that its placebo-arm infection rate ran well above what their own prophylaxed patients ever experienced. I want to be careful here, because I am not making the argument you might expect: his genotype is the more severe one, and the trial found benefit regardless of inheritance pattern, so nothing about being X-linked argues the drug does less for him. My argument is narrower. It is that a twelve-month pediatric result is being applied as a twenty-two-year adult mandate, and that no one has ever studied the thing we are actually doing to him. Combined with his six-year infection-free course and the real toll of three injections a week, a supervised discontinuation trial with a clear restart plan is something to offer him, not withhold.
Whatever happens with the interferon-gamma, I'd separate that question from the itraconazole. The antifungal piece of this regimen has its own dedicated randomized trial — Gallin and colleagues, 2003, itraconazole versus placebo for fungal prophylaxis in CGD — rather than resting on the same single study the interferon question does, and it's also the piece most likely to cause a problem in adulthood that childhood dosing didn't have to account for — absorption is inconsistent and dependent on gastric acidity, and it has real interaction potential with whatever medications come with an adult life he didn't have as a kid.
If we're reconsidering the regimen, I'd keep TMP-SMX and itraconazole as the settled core and treat interferon-gamma as the genuinely open question, not bundle all three into one decision.
Not resolved tonight, deliberately: the team agreed the itraconazole and TMP-SMX continue unchanged, but the interferon-gamma question was handed to Owen himself as a genuine choice rather than a recommendation the team converged on. He was given both readings honestly — the 1991 trial's real strength, and the fact that its twelve-month, largely pediatric design never tested the twenty-two-year adult course he has actually lived — and asked to take two weeks to decide, with a supervised discontinuation trial available if he wants one and no clinical pressure recorded either way in his chart.
He left without deciding. His own comment, quoted in the visit note because his immunologist thought it captured the actual stakes better than anything the team had said: 'I don't want to find out the shots were the reason by getting sick without them.'